Tocqueville Asset Management L.P. Makes New $1.05 Million Investment in MeiraGTx Holdings PLC $MGTX
Tocqueville Asset Management L.P. has made a new $1.05 million investment in MeiraGTx Holdings PLC (NASDAQ:MGTX), purchasing 77,700 shares. This increases institutional ownership to 67.48% of the company, with other firms like BlackRock Inc. and Deutsche Bank AG also acquiring new positions. The company recently reported strong quarterly results, beating EPS and revenue estimates, but has also seen insider selling activity.
MeiraGTx CEO Alexandria Forbes sells 62,000 shares for $859,320
MeiraGTx President and CEO Alexandria Forbes sold 62,000 ordinary shares on August 18, 2026, for $13.86 per share, totaling $859,320. This transaction reduced her direct holding to 1,325,695 ordinary shares. The information was originally published via EDGAR by MeiraGTx Holdings plc.
Meiragtx CEO Forbes sells $859,320 in company stock By Investing.com
Alexandria Forbes, CEO of MeiraGTx Holdings plc (NASDAQ:MGTX), sold 62,000 ordinary shares for $859,320 on August 18, 2026, as part of a Rule 10b5-1 trading plan. The shares were sold at an average price of $13.86, with Forbes directly owning 1,325,695 shares afterward. This transaction follows other company news, including a significant $400 million financial agreement with Oberland Capital and a reiterated Buy rating from H.C. Wainwright.
Alexandria Forbes Sells 62,000 Shares of MeiraGTx (NASDAQ:MGTX) Stock
MeiraGTx CEO Alexandria Forbes sold 62,000 shares of the company's stock for approximately $859,320 at an average price of $13.86, reducing her stake by 4.47%. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. MeiraGTx shares traded up 0.9% to $13.89, with the company recently reporting strong quarterly earnings of $1.71 per share against analyst expectations of ($0.46) and revenue of $321.43 million.
Meiragtx CEO Forbes sells $859,320 in company stock
MeiraGTx Holdings plc CEO Alexandria Forbes sold 62,000 ordinary shares for $859,320 as part of a pre-planned trading strategy. Following the sale, Forbes still directly owns over 1.3 million shares. The company recently secured up to $400 million in financing and received a reiterated Buy rating from H.C. Wainwright.
MeiraGTx (MGTX) holder readies new sale after recent 62K-share cashout
MeiraGTx Holdings plc (MGTX) has filed a Rule 144 notice indicating that Alexandria Forbes plans to sell 62,000 ordinary shares through Merrill Lynch, with an aggregate market value of $859,320. These shares were originally acquired on June 7, 2018, as an Incentive Compensation Stock Grant. The filing also reports that Forbes previously sold 62,000 ordinary shares on May 19, 2026, for $568,540.
MeiraGTx (MGTX) CEO sells 62K shares in preset plan at $13.86
MeiraGTx Holdings plc (MGTX) CEO Alexandria Forbes sold 62,000 Ordinary Shares at a weighted average price of $13.86 per share on August 18, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. Following the sale, Forbes directly holds 1,325,695 Ordinary Shares of MeiraGTx.
Johnson & Johnson Takes $89.72 Billion Position in MeiraGTx Holdings PLC $MGTX
Johnson & Johnson has acquired 6.64 million shares of MeiraGTx Holdings PLC, valued at approximately $89.72 billion, making it J&J's third-largest portfolio holding. This significant investment comes as MeiraGTx reported strong second-quarter earnings, exceeding analyst expectations, and received FDA Breakthrough Therapy Designation for one of its gene therapies. Despite the positive outlook from analysts, concerns about shareholder dilution from recent equity financing exist.
Profit Surge and New Leadership Might Change The Case For Investing In MeiraGTx Holdings (MGTX)
MeiraGTx Holdings (MGTX) recently reported a significant turnaround in its Q2 2026 financial results, with revenue jumping to US$321.43 million and net income improving to US$160.72 million from a previous loss. This shift to profitability, coupled with new leadership hires experienced in gene therapy commercialization, aims to re-position MeiraGTx as a fully integrated gene therapy company. Investors, however, should consider the sustainability of these profits and potential future dilution despite the positive near-term narrative.
Rubric Capital discloses 9.83% MeiraGTx (MGTX) position totaling 9.1M shares
Rubric Capital Management LP and David Rosen have reported a beneficial ownership of 9.83% in MeiraGTx Holdings plc, amounting to 9,100,000 Ordinary Shares. This disclosure was made in an amended Schedule 13G filing, indicating shared voting and dispositive power over these shares, which are held through Rubric-managed funds. The ownership percentage is based on 92,609,516 Ordinary Shares outstanding as of May 8, 2026.
MeiraGTx (MGTX) Stock Jumps After Profit Shock Raises Durability Questions
MeiraGTx (MGTX) stock surged 6.7% after the company reported a significant and unexpected swing to profitability in Q2 2026, with basic EPS of US$1.76 and net income of US$160.72 million on US$321.43 million in revenue. This profit surprise, combined with late-stage pipeline progress and non-dilutive funding, suggests an evolution from a pure pipeline story to a more financially grounded platform. However, the durability of these earnings is questioned, as clinical-stage biotech profits can be volatile and potentially stem from one-off events, leaving the stock's long-term risk profile still in view.
MeiraGTx Holdings Releases Q2 2026 Financial Results
MeiraGTx Holdings plc reported a significant turnaround in Q2 2026, swinging to profitability with diluted earnings per share of $1.71, compared to a loss in the previous year. The company achieved substantial revenue growth, reaching $321.4M from $3.7M in Q2 2025, indicating a commercial milestone in its genetic medicines pipeline. Wall Street analysts maintain a bullish outlook on the stock, reflecting strong investor confidence in MeiraGTx's commercialization efforts and genetic medicines portfolio.
Sei Investments Co. Buys Shares of 99,627 MeiraGTx Holdings PLC $MGTX
Sei Investments Co. has acquired 99,627 shares of MeiraGTx Holdings PLC (MGTX) worth approximately $863,000, as part of broader institutional investor interest in the company. Despite significant insider selling totaling $1.68 million over the last three months, MeiraGTx reported strong quarterly EPS of $1.71, surpassing estimates, and analysts maintain a "Moderate Buy" rating with an average price target of $26. The company is a clinical-stage biotechnology firm focused on developing gene therapies for rare diseases.
Why is MeiraGTx stock surging today?
MeiraGTx Holdings PLC stock surged 6.3% following a dramatic beat on Q2 2026 earnings, reporting $1.71 EPS against an expected loss and revenue of $321.4 million. The company's financial turnaround was supported by strategic deals, FDA Breakthrough Therapy Designation, and a significantly strengthened balance sheet. These positive developments, combined with a favorable market, suggest an accelerating transformation for MeiraGTx from a clinical-stage developer to a revenue-generating enterprise.
MeiraGTx Holdings Releases Q2 2026 Financial Results
MeiraGTx Holdings plc (MGTX) reported a significant turnaround in Q2 2026, swinging to profitability with diluted earnings per share of $1.71 and net income of $160.7M. The company's revenue surged to $321.4M from $3.7M in Q2 2025, indicating a major commercial milestone in its transition from a clinical-stage to a commercial-stage genetic medicines firm. Wall Street analysts maintain a bullish stance on the stock, reflecting investor confidence in MeiraGTx's genetic medicines portfolio.
MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
MeiraGTx Holdings PLC (MGTX) reported Q2 earnings of $1.71 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.39 per share, and revenue of $321.43 million, which also surpassed expectations. Despite the strong quarterly performance, the company holds a Zacks Rank #3 (Hold), suggesting its shares are expected to perform in line with the market in the near future. MeiraGTx shares have seen a 63% increase year-to-date, outperforming the S&P 500.
Form 8K MeiraGTx Holdings PLC For: 13 August By Investing.com
This article reports on a Form 8K filing by MeiraGTx Holdings PLC for August 13th, as published by Investing.com. It is a brief announcement without further details regarding the content of the filing. The article is primarily a placeholder for the SEC filing information.
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
MeiraGTx Holdings plc announced its second-quarter 2026 financial and operational results, highlighting significant progress in transforming into a commercial company. Key achievements include the acquisition of botaretigene sparoparvovec (bota-vec) for XLRP, FDA Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia (RIX) with positive three-year data, and securing up to $400 million in strategic investment from Oberland Capital. The company plans global regulatory filings for bota-vec in 2026 and a potential BLA filing for AAV2-hAQP1 in mid-2027, alongside advancing its Riboswitch platform and other programs.
MeiraGTx Holdings plc 2026: Revenue $321.43M, EPS $1.71— 10-Q Summary
MeiraGTx Holdings plc reported strong financial results for the 2026 quarter, with revenue soaring to $321.43 million and diluted EPS reaching $1.71. This significant growth was primarily driven by increased service and related-party revenue from a Lilly contract, as well as the recognition of deferred arrangements. The company also highlighted pipeline advancements, strategic collaborations, and manufacturing progress in its business highlights.
MeiraGTx Holdings PLC (NASDAQ:MGTX) Given Average Rating of "Moderate Buy" by Brokerages
MeiraGTx Holdings PLC (NASDAQ:MGTX) has received an average "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $26.00, significantly above its current trading price of $12.96. Despite recent insider share sales by the CEO and CFO totaling $1.68 million, insiders still retain a 7.4% ownership stake. The company, which has a market capitalization of $1.2 billion, reported a quarterly loss of $0.57 per share but revenue of $0.29 million, falling short of analyst expectations.
MeiraGTx Holdings PLC (MGTX) Stock News Today
This article from TradingKey provides stock information for MeiraGTx Holdings PLC (MGTX). It includes current stock price, market capitalization, and indicates that more news, earnings, and analyst ratings for MGTX are expected soon. The page serves as a hub for MGTX stock-related updates.
MeiraGTx Holdings plc (MGTX) Stock Analysis: Exploring a 128.97% Potential Upside in the Biotech Arena
MeiraGTx Holdings plc (NASDAQ: MGTX) is a clinical-stage biotechnology company with a market capitalization of $1.18 billion, focusing on genetic therapies for ocular, neurodegenerative, and autoimmune diseases. Analysts show strong optimism with all seven ratings being "Buy" and an average target price of $29.29, suggesting a 128.97% potential upside despite recent revenue decline. The company is strategically positioned with a robust pipeline, strong cash flow, and collaborations with industry leaders, making it an intriguing, albeit risky, investment in the biotech sector.
MeiraGTx grants new hire 75,000 stock options under inducement plan
MeiraGTx has granted a new hire 75,000 non-qualified stock options and 75,000 time-based Restricted Stock Units (RSUs) under its 2026 Employment Inducement Award Plan. The stock options will vest over 36 months, with 25% after one year, while the RSUs will vest 50% after two years and then 25% in years three and four, all contingent on continued employment.
MeiraGTx Holdings PLC (MGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates
MeiraGTx Holdings PLC (MGTX) has an earnings forecast score of 8.50, ranking 108th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $27.00 for MGTX, with a "Buy" trend based on ratings from 7 analysts. The company's expected revenue for the next quarter is $12.48 million, and EPS for the next quarter is anticipated to be -$0.46.
MeiraGTx grants new hire 75,000 stock options under inducement plan
MeiraGTx has granted a new hire 75,000 non-qualified stock options and 75,000 time-based Restricted Stock Units (RSUs) under its 2026 Employment Inducement Award Plan. The stock options are priced at the Nasdaq closing price on the employee's start date and vest over four years, while the RSUs also vest over four years with specific percentages at two, three, and four years. This move is designed to incentivize and retain the new employee.
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MeiraGTx Holdings plc announced that its Compensation Committee approved equity awards for a new employee. These awards, consisting of non-qualified stock options and time-based restricted stock units, were granted as an inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are subject to vesting schedules tied to continued employment.
A new MeiraGTx employee receives 150,000 equity awards
MeiraGTx (Nasdaq: MGTX) announced that its Compensation Committee approved an inducement grant of 75,000 non-qualified stock options and 75,000 time-based Restricted Stock Units (RSUs) for a new employee. These awards, made under Nasdaq Listing Rule 5635(c)(4), are contingent on continued employment, with specific vesting schedules over one to four years. The stock options' exercise price will be the closing price of MeiraGTx ordinary shares on the employee's start date.
MeiraGTx Holdings PLC (328.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance
The article provides an overview of analyst recommendations and price targets for MeiraGTx Holdings PLC (328.SG). It lists several recent analyst actions, including RBC Capital and HC Wainwright & Co. maintaining "Outperform" and "Buy" ratings respectively. The stock currently trades at 11.10 EUR with no change, as of the latest market data.
MeiraGTx Holdings (Nasdaq:MGTX) - Stock Analysis
MeiraGTx Holdings (MGTX) is a clinical-stage genetic medicines company with a market cap of US$1.1 billion. The company faces financial risks including negative shareholder equity, unprofitability, and past shareholder dilution, though revenue is forecast to grow significantly. Recent developments include a $400 million financing package to accelerate its gene therapy pipeline, positive clinical trial data for AAV-hAQP1 in radiation-induced xerostomia, and FDA Regenerative Medicine Advanced Therapy (RMAT) designations for AAV-GAD and AAV2-hAQP1.
MeiraGTx Holdings PLC (MGTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of MeiraGTx Holdings PLC (MGTX), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. While the current price momentum score is 4.55 within the Biotechnology & Medical Research industry, technical indicators collectively suggest a "Neutral" signal for the stock. The article advises that MGTX is currently trading between specified resistance and support levels, making it potentially suitable for range-bound swing trading.
MGTX|MeiraGTx Holdings PLC|Price:11.810|Chg%:-0.490
MeiraGTx Holdings PLC (MGTX) has a high growth potential and relatively healthy fundamentals, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. The company, a clinical-stage genetic medicines firm with several late-stage clinical programs, has shown strong revenue and profit growth. Analysts have rated it as a Buy, with expectations for its stock price to trend upward in the medium term despite recent weak market performance.
Price to earnings forward of MeiraGTx Holdings Plc – LS:A2JGHF
This article provides financial information for MeiraGTx Holdings Plc, identified by the stock symbol LS:A2JGHF on the Lang & Schwarz Tradecenter. It specifically focuses on the company's forward price-to-earnings ratio and indicates that the market is currently closed with no trades. The content is primarily a data placeholder within a financial platform, offering an overview of the company's financials, news, and technical data.
Rubric Capital Management LP Acquires 824,669 Shares of MeiraGTx Holdings PLC $MGTX
Rubric Capital Management LP increased its stake in MeiraGTx Holdings PLC by 13.4% in the first quarter, purchasing 824,669 additional shares and bringing its total holdings to 7 million shares, representing 7.56% of the company. Despite reporting a quarterly loss of $0.57 per share (better than estimates) and revenue of $0.29 million (below consensus), MeiraGTx maintains an average "Moderate Buy" rating from analysts with a $26 price target. Institutional investors collectively own 67.48% of the stock, while company insiders hold 7.40% and have recently sold shares under Rule 10b5-1 trading plans.
MeiraGTx Holdings PLC (MGTX) Institutional Confidence
MeiraGTx Holdings PLC (MGTX) has an institutional shareholding score of 5.00, placing it 132nd in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 59.59%, a 4.66% decrease quarter-over-quarter. Bill Nygren | OAKMX is the largest institutional shareholder, holding 62.13K shares, despite an 84.48% decrease in their overall holdings.
MeiraGTx Holdings PLC (MGTX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of MeiraGTx Holdings PLC (MGTX), listing major shareholders like Sanofi SA and Perceptive Advisors LLC. It breaks down shareholder types, institutional holdings over several quarters, and recent shareholder activity including changes in positions. The piece also identifies various ETFs with holdings in MGTX.
MeiraGTx Holdings PLC (MGTX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical dividend and stock split information for MeiraGTx Holdings PLC (MGTX). It indicates that the company has distributed a total of $0.00 USD in dividends over the past five years, with no specific dividend data available. The content primarily serves as a placeholder for financial data related to dividends and stock splits for MGTX.
MeiraGTx Holdings Market Sentiment
This article provides an overview of MeiraGTx Holdings' (MGTX) market sentiment, including analyst consensus, short interest, options flow, and insider activity. Key signals indicate a "Buy" consensus from analysts, 7.2% declining short interest, and net seller activity from insiders over the last 30 days. The average price target from analysts is $25, suggesting a potential upside of 111.1%.
MeiraGTx Holdings PLC MGTX Income Statement
This article provides a detailed quarterly and annual income statement for MeiraGTx Holdings PLC (MGTX), offering insights into its financial performance, including total revenue, operating expenses, and net income over several fiscal years and quarters. It also includes an FAQ section to help users understand how to interpret the financial data presented on TradingKey.
MGTX|MeiraGTx Holdings PLC|Price:11.770|Chg%:-0.330
This article provides a comprehensive financial overview of MeiraGTx Holdings PLC (MGTX), detailing its stock performance, key financial indicators, and earnings reports. It includes an analysis of income statements, balance sheets, and cash flow statements, offering data for both quarterly and annual periods. The report also addresses frequently asked questions regarding the company's revenue, assets, liabilities, equity, and profitability metrics.
MeiraGTx Holdings PLC (MGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for MeiraGTx Holdings PLC (MGTX), highlighting its current earnings forecast score, average price target of $27.00, and analyst ratings. Based on 8 analysts, the stock has a "Buy" trend with a potential upside of 134.50%. It also covers expected revenue for the next quarter ($24.85M) and past EPS performance.
MeiraGTx Holdings Plc Revenue Breakdown – FWB:328
MeiraGTx Holdings Plc (FWB:328) generated €69.30 million in revenue last year, primarily from its Genetic Medicines segment. The United Kingdom was the largest contributor to this revenue. This marks an increase from €32.15 million the previous year.
MGTX|MeiraGTx Holdings PLC|Price:11.770|Chg%:-0.330
This article provides a detailed company profile for MeiraGTx Holdings PLC (MGTX), a clinical-stage genetic medicines company specializing in treatments for prevalent disorders like Parkinson's disease and various ocular conditions. It outlines the company's product pipeline, key executives, and institutional shareholding data.
MGTX|MeiraGTx Holdings PLC|Price:11.770|Chg%:-0.330
MeiraGTx Holdings PLC (MGTX) experienced a slight dip of 2.73% on July 24, 2026, closing at $11.770. Despite this, the company's fundamentals are considered healthy with high growth potential and a "Buy" rating from multiple analysts, who set the highest price target at $28.38. MeiraGTx is a clinical-stage genetic medicines company focused on developing treatments for various disorders including Parkinson’s disease and retinal dystrophies.
MeiraGTx CFO, COO Richard Giroux disposes of 56,000 shares for $700,560
MeiraGTx's CFO and COO, Richard Giroux, sold 56,000 ordinary shares on July 21, 2026, for a total of $700,560 at a weighted average price of $12.51 per share. Following this transaction, Giroux's direct holdings in the company decreased to 908,530 ordinary shares. The information for this news brief was generated by AI using data published by MeiraGTx Holdings plc via the U.S. SEC's EDGAR system.
MGTX (MGTX) affiliate files to sell 56,000 ordinary shares via Form 144
An affiliate of MGTX has filed a Form 144 to sell up to 56,000 ordinary shares through Merrill Lynch on the NASDAQ market. The aggregate market value of these shares is $700,560, and they originate from Incentive Compensation Stock Grants issued in late 2018. The proposed sale date for these shares is July 21, 2026.
Form 4 MeiraGTx Holdings PLC For: 21 July By Investing.com
This article from Investing.com reports on a Form 4 filing for MeiraGTx Holdings PLC, specifically mentioning activity on July 21. It indicates a slight dip in the stock price for MGTX. The content primarily consists of market data and related news headlines surrounding the main topic.
Form 4 MeiraGTx Holdings PLC For: 21 July By Investing.com
This article from Investing.com reports on a Form 4 filing for MeiraGTx Holdings PLC, dated July 21. Form 4s disclose changes in beneficial ownership of a company's securities by its directors, officers, and principal stockholders. The specific details of the filing are not provided in the snippet, but it highlights the company's stock symbol MGTX and its performance on July 22, 2026.
MeiraGTx CFO & COO Giroux sells $700,560 in shares By Investing.com
Richard Giroux, CFO and COO of MeiraGTx Holdings plc (NASDAQ:MGTX), sold 56,000 ordinary shares worth $700,560 on July 21, 2026, under a pre-arranged trading plan. This sale occurred while the company's shares have seen significant gains year-to-date and are trading near its market capitalization of $1.16 billion. The transaction follows recent positive developments for MeiraGTx, including a $400 million investment agreement, strategic collaborations for gene therapies, and raised price targets from analysts.
MeiraGTx Holdings (NASDAQ: MGTX) CFO sells 56,000 shares in plan trade
MeiraGTx Holdings' CFO & COO, Richard Giroux, sold 56,000 Ordinary Shares on July 21, 2026, at a weighted average price of $12.51 per share, following a Rule 10b5-1 trading plan adopted in November 2025. After these transactions, Giroux directly holds 908,530 Ordinary Shares, with additional indirect holdings through his spouse and Aigle Healthcare Partners III LLC. The sale reflects a scheduled transaction rather than a discretionary one.
Form 144 MEIRAGTX HOLDINGS PLC For: 21 July By Investing.com
This article reports on a Form 144 filing by MEIRAGTX HOLDINGS PLC for July 21st. It briefly notes the company's stock symbol MGTX and its current performance (+2.54%). The content primarily serves as a placeholder for the filing information, surrounded by general financial market data.
